• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International clinical psychopharmacology >Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone.
【24h】

Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone.

机译：稳定的精神病患者的改善已从口服常规抗精神病药物治疗改为长效利培酮。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Recent meta-analytic work suggests atypical antipsychotics may be clinically superior to conventional antipsychotics, although many stable patients remain on conventional antipsychotic treatment. A long-acting atypical agent may benefit patients in realms of both advanced medication delivery and mechanism of action. In a multicentre, open-label study of 725 patients with schizophrenia or schizoaffective disorder, patients received 25-75 mg of long-acting risperidone every 2 weeks for up to 50 weeks, with performance of standard safety and efficacy assessments. Data are presented on stable patients receiving oral conventional antipsychotics at study entry. In the 46 (6.3%) stable patients receiving oral conventional antipsychotics (followed between 6 months and 1 year; mean 468 days), mean (SD) Positive and Negative Syndrome Scale (PANSS) total score improved from 73.1+/-17.2 to 64.5+/-18.2 (P=0.0006). Clinical improvement of > or =20%, > or =40% or > or =60% reduction in PANSS total score occurred in 49%, 29% and 10% of stable patients, respectively. Extrapyramidal Symptom Rating Scale subjective ratings and objective physician ratings (parkinsonism) decreased significantly (P<0.05). The hypothesis that switching stable patients treated with oral conventional antipsychotics to long-acting risperidone may result in significant improvements in psychiatric and movement disorder symptomatology merits further investigation.
机译：最近的荟萃分析工作表明，尽管许多稳定的患者仍接受常规抗精神病药物治疗，但非典型抗精神病药物在临床上可能优于常规抗精神病药物。长效非典型药物可能在晚期药物输送和作用机制方面使患者受益。在一项对725名精神分裂症或精神分裂症患者进行的多中心，开放标签研究中，患者每2周接受25-75 mg长效利培酮治疗，长达50周，并进行标准安全性和有效性评估。数据显示在研究开始时接受口服常规抗精神病药治疗的稳定患者。在接受口服常规抗精神病药治疗的46位（6.3％）稳定患者中（随访时间为6个月至1年;平均468天），平均（SD）阳性和阴性综合征量表（PANSS）的总评分从73.1 +/- 17.2改善到64.5 +/- 18.2（P = 0.0006）。分别有49％，29％和10％的稳定患者发生PANSS总评分降低≥20％，≥40％或≥60％的临床改善。锥体外系症状分级量表的主观评分和客观医师评分（帕金森综合症）显着降低（P <0.05）。将稳定的口服常规抗精神病药治疗的患者改用长效利培酮的假说可能会导致精神病和运动障碍症状的显着改善，值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号